We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $499M
1-Year Est. Return 186.05%
This Fund
S&P 500
This Quarter Est. Return
+6.52%
1 Year Est. Return
+186.05%
3 Year Est. Return
+672.09%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$517M
AUM Growth
+$19.8M
Cap. Flow
-$2.75M
Cap. Flow %
-0.53%
Top 10 Hldgs %
81.3%
Holding
59
New
10
Increased
8
Reduced
9
Closed
13

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$8.15M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$5.53M
3
CLDX icon
Celldex Therapeutics
CLDX
+$2.84M
4
IONS icon
Ionis Pharmaceuticals
IONS
+$2.56M
5
SLNO
Soleno Therapeutics
SLNO
+$2.27M

Top Sells

Rank Stock Value
1
ABBV icon
AbbVie
ABBV
+$16.5M
2
ARGX icon
argenx
ARGX
+$7.31M
3
CYTK icon
Cytokinetics
CYTK
+$6.28M
4
VRTX icon
Vertex Pharmaceuticals
VRTX
+$4.34M
5
INSM icon
Insmed
INSM
+$2.51M

Sector Composition

Rank Sector Weight
1 Healthcare 75.36%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NVO
1
Novo Nordisk
NVO
$216B
$98.7M 19.09%
691,743
– –
LLY icon
2
Eli Lilly
LLY
$1.07T
$83.8M 16.2%
92,593
– –
LLY icon
3
PUT
Eli Lilly
LLY
$1.07T
$67.9M 13.13%
75,000
-40,000
-35% -$32M
MRK icon
4
Merck
MRK
$324B
$54.8M 10.59%
442,504
+63,304
+17% +$8.15M
NVO
5
PUT
Novo Nordisk
NVO
$216B
$44.2M 8.55%
+310,000
New +$41.1M
VKTX icon
6
Viking Therapeutics
VKTX
$4.04B
$24M 4.64%
452,979
+19,399
+4% +$1.27M
AZN icon
7
AstraZeneca
AZN
$263B
$14.9M 2.88%
95,376
– –
ITCI
8
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$14.8M 2.87%
216,519
+6,423
+3% +$445K
VRTX icon
9
Vertex Pharmaceuticals
VRTX
$121B
$8.86M 1.71%
18,900
-10,000
-35% -$4.34M
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$36.3B
$8.51M 1.64%
+35,000
New +$5.53M
VKTX icon
11
CALL
Viking Therapeutics
VKTX
$4.04B
$7.95M 1.54%
+150,000
New +$9.83M
INSM icon
12
PUT
Insmed
INSM
$23.2B
$7.37M 1.42%
+110,000
New +$4.27M
AXSM icon
13
Axsome Therapeutics
AXSM
$12.4B
$7.07M 1.37%
87,848
– –
ARGX icon
14
argenx
ARGX
$57.4B
$6.51M 1.26%
15,138
-19,100
-56% -$7.31M
NBIX icon
15
Neurocrine Biosciences
NBIX
$17.7B
$6.2M 1.2%
45,000
– –
PCVX icon
16
Vaxcyte
PCVX
$7.89B
$5.76M 1.11%
76,255
– –
PTGX icon
17
Protagonist Therapeutics
PTGX
$8.75B
$4.31M 0.83%
124,440
– –
DYN icon
18
Dyne Therapeutics
DYN
$4.04B
$4.22M 0.82%
119,488
– –
SLNO
19
DELISTED
Soleno Therapeutics
SLNO
$3.85M 0.74%
94,424
+53,500
+131% +$2.27M
CRNX icon
20
Crinetics Pharmaceuticals
CRNX
$8.86B
$3.84M 0.74%
85,765
– –
INSM icon
21
Insmed
INSM
$23.2B
$3.58M 0.69%
53,436
-64,800
-55% -$2.51M
OCUL icon
22
Ocular Therapeutix
OCUL
$1.86B
$3.42M 0.66%
500,000
-224,685
-31% -$1.39M
IONS icon
23
Ionis Pharmaceuticals
IONS
$9.35B
$2.98M 0.58%
+62,479
New +$2.56M
MRUS
24
DELISTED
Merus
MRUS
$2.97M 0.57%
50,171
– –
CLDX icon
25
Celldex Therapeutics
CLDX
$2.77B
$2.79M 0.54%
+75,300
New +$2.84M
1
2 3

Similar funds

MIP
Marietta Investment Partners Milwaukee, Wisconsin $499M AUM 41.06% 1-Year Est. Return
H2CM
H/2 Credit Manager Stamford, Connecticut $500M AUM 24.68% 1-Year Est. Return
HCI
Harraden Circle Investments New York $499M AUM 24.03% 1-Year Est. Return
KCL
KR Capital LP New York City, New York $499M AUM
PPC
Park Place Capital Homewood, Alabama $499M AUM 14.38% 1-Year Est. Return
HIC
Holderness Investments Company Greensboro, North Carolina $498M AUM 34.39% 1-Year Est. Return
CWM
Centric Wealth Management Chicago, Illinois $501M AUM 15.27% 1-Year Est. Return
HSG
Helen Stephens Group Fort Worth, Texas $501M AUM 16.23% 1-Year Est. Return

Artia Global Partners's Q2 2024 Portfolio in Review

As of Q2 2024, Artia Global Partners held 59 positions worth $517M, up 4% from $498M the previous quarter. Its ten largest holdings account for 81% of the portfolio.

Artia Global Partners's Q2 2024 filing shows 10 new, 8 increased, 9 reduced and 13 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 35,000 shares worth $8.51M. The largest sale was AbbVie, an estimated $16.5M.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, down from 82% a quarter earlier.

  • Artia Global Partners's largest Q2 2024 buy was Alnylam Pharmaceuticals: 35,000 shares worth $8.51M.
  • Artia Global Partners added most to Merck in Q2 2024, an estimated $8.15M increase.
  • Artia Global Partners's biggest Q2 2024 reduction was argenx, cutting an estimated $7.31M.
  • Artia Global Partners fully exited AbbVie in Q2 2024, selling an estimated $16.5M.
  • Artia Global Partners's ten largest holdings make up 81% of its $517M portfolio in Q2 2024.
  • Artia Global Partners opened 10 new positions and closed 13 in Q2 2024.
  • Artia Global Partners's portfolio value rose 4% quarter-over-quarter to $517M.

Based on Artia Global Partners's 13F filing for Q2 2024, filed 14 Aug 2024.